

Emily Chu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/299078/publications.pdf>

Version: 2024-02-01

80
papers

1,364
citations

430874

18
h-index

377865

34
g-index

80
all docs

80
docs citations

80
times ranked

2205
citing authors

#	ARTICLE	IF	CITATIONS
1	Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1265-1272.	1.2	166
2	Cutaneous Manifestations of <i>DOCK8</i> Deficiency Syndrome. <i>Archives of Dermatology</i> , 2012, 148, 79.	1.4	129
3	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation. <i>Nature Communications</i> , 2017, 8, 15397.	12.8	104
4	Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. <i>JAMA Dermatology</i> , 2018, 154, 1057.	4.1	86
5	Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 787-791.	1.3	63
6	Association Between Patient Age and Lymph Node Positivity in Thin Melanoma. <i>JAMA Dermatology</i> , 2017, 153, 866.	4.1	50
7	Coxsackievirus A6-Induced Hand-Foot-Mouth Disease. <i>JAMA Dermatology</i> , 2013, 149, 1419.	4.1	49
8	Patients' Preferences for Biopsy Result Notification in an Era of Electronic Messaging Methods. <i>JAMA Dermatology</i> , 2015, 151, 513.	4.1	47
9	Reliability and Convergent Validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for Assessing Cutaneous Sarcoidosis. <i>JAMA Dermatology</i> , 2013, 149, 550.	4.1	40
10	Clinical factors associated with subclinical spread of in situ melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 707-713.	1.2	36
11	Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 74-77.	1.3	34
12	Evaluation of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme for diagnosis of cutaneous melanocytic neoplasms: Results from the International Melanoma Pathology Study Group. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 356-363.	1.2	30
13	Clinical and pathologic factors associated with subclinical spread of invasive melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 714-721.	1.2	30
14	Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. <i>JAMA Dermatology</i> , 2018, 154, 1401.	4.1	30
15	The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: A single institution experience. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1096-1098.	1.2	30
16	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	4.1	29
17	<i>CDKN2A</i> mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. <i>British Journal of Dermatology</i> , 2016, 175, 785-789.	1.5	27
18	The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 245-251.	1.2	26

#	ARTICLE	IF	CITATIONS
19	Association of Marital Status With T Stage at Presentation and Management of Early-Stage Melanoma. <i>JAMA Dermatology</i> , 2018, 154, 574.	4.1	19
20	Mucinous Nevus. <i>JAMA Dermatology</i> , 2014, 150, 1018.	4.1	18
21	Photoinduced distributed lichenoid eruption secondary to direct antiviral therapy for hepatitis C. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 769-773.	1.3	17
22	Shiitake dermatitis: a report of 3 cases and review of the literature. <i>Cutis</i> , 2013, 91, 287-90.	0.3	17
23	Lymphedematous verrucous changes simulating squamous cell carcinoma in long-standing hidradenitis suppurativa. <i>International Journal of Dermatology</i> , 2013, 52, 808-812.	1.0	14
24	Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma. <i>JAMA Dermatology</i> , 2016, 152, 836.	4.1	14
25	p15 Expression Differentiates Nevus from Melanoma. <i>American Journal of Pathology</i> , 2016, 186, 3094-3099.	3.8	14
26	Impact of a smartphone application on skin self-examination rates in patients who are new to total body photography: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 564-567.	1.2	14
27	Vemurafenib-induced interface dermatitis manifesting as radiation recall and a keratosis pilaris-like eruption. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 539-543.	1.3	13
28	Piloting the Use of Smartphones, Reminders, and Accountability Partners to Promote Skin Self-Examinations in Patients with Total Body Photography: A Randomized Controlled Trial. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 779-785.	6.7	13
29	The histopathologic features of Integra® Dermal Regeneration Template. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 368-369.	1.3	12
30	Comparison of C3d immunohistochemical staining to enzyme-linked immunosorbent assay and immunofluorescence for diagnosis of bullous pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 172-178.	1.2	11
31	Assessment of smartphone applications for total body digital photography-guided skin exams by patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1063-1064.e1.	1.2	10
32	Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 5207-5216.	1.5	10
33	Pembrolizumab-induced sarcoidal infusion site reaction. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 727-729.	1.3	9
34	Gene Expression Profile Testing for Thin Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 837.	4.1	9
35	Association of the Affordable Care Act's Medicaid expansion with the diagnosis and treatment of clinically localized melanoma: A National Cancer Database study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1628-1635.	1.2	9
36	Sorafenib-Induced Eruption Mimicking Erythema Multiforme. <i>JAMA Dermatology</i> , 2016, 152, 227.	4.1	8

#	ARTICLE	IF	CITATIONS
37	Use of new molecular tests for melanoma by pigmented-lesion experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 245-247.	1.2	8
38	An Inpatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome. <i>JAMA Dermatology</i> , 2020, 156, 676.	4.1	8
39	Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy. <i>Immunotherapy</i> , 2020, 12, 951-956.	2.0	7
40	Vogtâ€“Koyanagiâ€“Haradaâ€“like syndrome in the setting of combined antiâ€“PD1/antiâ€“CTLA4 therapy. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1111-1112.	1.3	7
41	Sentinel lymph node biopsy in patients with clinical stage IIB/C cutaneous melanoma: A national cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 754-760.	1.2	7
42	The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma. <i>Current Dermatology Reports</i> , 2013, 2, 84-100.	2.1	6
43	Differential Tâ€“cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals. <i>Experimental Dermatology</i> , 2016, 25, 245-247.	2.9	6
44	Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweetâ€“like Infiltrate. <i>JAMA Dermatology</i> , 2017, 153, 719.	4.1	6
45	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 190-194.	1.3	6
46	Association between halo nevi and melanoma in adults: A multicenter retrospective case series. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1164-1166.	1.2	6
47	Distinct Signatures of Genomic Copy Number Variants Define Subgroups of Merkel Cell Carcinoma Tumors. <i>Cancers</i> , 2021, 13, 1134.	3.7	6
48	Alcohol-induced vasculitis: Case report and commentary. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, e42-e43.	1.2	5
49	Expression of p15 in a spectrum of spitzoid melanocytic neoplasms. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 310-316.	1.3	5
50	Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 860-869.	1.2	5
51	The accuracy of detecting melanoma on frozen section melanoma antigen recognized by T cells 1 (MART-1) stains and on permanent sections of previously frozen tissue: A prospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1764-1766.	1.2	5
52	Diverse landscape of dermatologic toxicities from smallâ€“molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	1.3	5
53	Development of <i>RET</i> mutant cutaneous angiosarcoma during <i>BRAF</i> inhibitor therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1053-1056.	1.3	4
54	MART-1-labeled melanocyte density and distribution in actinic keratosis and squamous cell cancer in situ: Pagetoid melanocytes are a potential source of misdiagnosis as melanoma in situ. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 734-742.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Optimizing Detection of Lymphatic Invasion in Primary Cutaneous Melanoma With the Use of D2-40 and a Paired Melanocytic Marker. <i>American Journal of Dermatopathology</i> , 2022, 44, 21-27.	0.6	4
56	Generalized congenital epithelioid blue nevi (pigmented epithelioid melanocytomas) in an infant: Report of case and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 954-959.	1.3	3
57	Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade. <i>Surgical Pathology Clinics</i> , 2021, 14, 209-224.	1.7	3
58	Acral lentiginous melanoma in the era of immune checkpoint blockade and targeted therapy: A National Cancer Database analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 169-172.	1.2	3
59	Cutaneous Metastases of Melanoma Mimicking Interstitial Granulomatous Processes. <i>American Journal of Dermatopathology</i> , 2018, 40, 706-707.	0.6	2
60	A Blue-Gray Macule on the Back: Answer. <i>American Journal of Dermatopathology</i> , 2020, 42, 65-65.	0.6	2
61	Presentation of Acute Megakaryoblastic Leukemia Associated with a GATA1 Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder. <i>Pediatric Dermatology</i> , 2015, 32, e204-7.	0.9	1
62	Lymphedematous verrucous changes of the genital skin: an extraintestinal manifestation of Crohn disease. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 465-468.	1.3	1
63	Local recurrence in patients undergoing wide excision and sentinel lymph node biopsy for cutaneous malignant melanoma: A single-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 247-250.	1.2	1
64	Association Between Underlying Comorbid Conditions and Stage of Presentation in Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	1
65	Reply to: "Statistical and methodological issues". <i>Journal of the American Academy of Dermatology</i> , 2017, 77, e115-e116.	1.2	0
66	SnapshotDx Quiz: March 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e31.	0.7	0
67	SnapshotDx Quiz: July 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e47.	0.7	0
68	A Blue-Gray Macule on the Back: Challenge. <i>American Journal of Dermatopathology</i> , 2020, 42, e4-e4.	0.6	0
69	SnapshotDx Quiz: November 2020. <i>Journal of Investigative Dermatology</i> , 2020, 140, e121-e126.	0.7	0
70	Urethral involvement is associated with higher mortality and local recurrence in vulvar melanoma: a single institutional experience. <i>Human Pathology</i> , 2020, 104, 1-8.	2.0	0
71	Evaluation of the Merits and Limitations of Evidence-Based Medicine. <i>JAMA Dermatology</i> , 2020, 156, 924.	4.1	0
72	SnapshotDx Quiz: March 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e27-e32.	0.7	0

#	ARTICLE	IF	CITATIONS
73	SnapshotDx Quiz: July 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e77-e82.	0.7	0
74	Shedding Light on Disparities in Melanoma Care. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1625-1626.	0.7	0
75	Response to a letter to the editor regarding "limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population-level". <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e197-e198.	1.2	0
76	<i>NRAS</i> and <i>BRAF</i> mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib. <i>Journal of Clinical Oncology</i> , 2013, 31, 9017-9017.	1.6	0
77	ASO Visual Abstract: Prognostic Significance of Primary-Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
78	SnapshotDx Quiz: March 2022. <i>Journal of Investigative Dermatology</i> , 2022, 142, e27-e32.	0.7	0
79	Slow-Growing Nodule in a Patient With Li-Fraumeni Syndrome: Challenge. <i>American Journal of Dermatopathology</i> , 2022, 44, e37-e38.	0.6	0
80	Slow-Growing Nodule in a Patient With Li-Fraumeni Syndrome: Answer. <i>American Journal of Dermatopathology</i> , 2022, 44, 312-313.	0.6	0